Earnings call transcript: Arrow Electronics Q4 2024 beats expectations
Inc. reported its fourth-quarter results for 2024, surpassing market expectations with non-GAAP earnings per share (EPS) of $2.97, exceeding the forecasted $2.64. The company also posted revenues of ...
The Financial Express27d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
Key contributors include Breztri Aerosphere, a triple-combination inhaler, and Fasenra, both of which are undergoing indication expansions to serve broader patient populations. The company ...
Pharmaceutical Technology1mon
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
Key drivers include Breztri Aerosphere (budesonide, formoterol fumarate, and glycopyrrolate) and Fasenra, both of which are positioned for indication expansions into severe asthma and COPD. The first ...